ADVFN - Advanced Financial Network.
HOME» NASDAQ » I » IMGN Stock Price » IMGN Stock News

Immunogen Share News

 Immunogen (mm) Stock Price
IMGN Stock Price
 Immunogen (mm) Stock Chart
IMGN Stock Chart
 Immunogen (mm) Stock News
IMGN Stock News
 Immunogen (mm) Company Information
IMGN Company Information
 Immunogen (mm) Stock Trades
IMGN Stock Trades

US Stock Futures: HOT STOCKS TO WATCH

Among the companies whose shares are expected to actively trade in Tuesday's session are General Mills Inc. (GIS), AT&T Inc. (T) and Navistar International Corp.'s (NAV). General Mills's fiscal second-quarter earnings fell 28% as higher costs continued to outpace the food giant's sales growth. Shares slipped 2.8% to $38.50 in recent premarket trade. AT&T bowed to U.S. antitrust authorities and withdrew its $39 billion acquisition of T-Mobile USA, ending a nine-month fight to complete a deal many saw as a long shot and leaving both carriers groping for a way forward. The high-profile defeat came after AT&T had already pulled its application from the Federal Communications Commission and put on hold efforts to fight the Justice Department's suit to block the deal. AT&T shares fell 0.8% to $28.50 premarket. Competitor Sprint Nextel Corp. (S), meanwhile, jumped 6.9% to $2.31 on the news. Clearwire Corp. (CLWR) a major Sprint partner, was up 4.9% at $2.14. Navistar's fiscal fourth-quarter earnings surged as the commercial truck manufacturer saw its margins widen and profits grow in all major segments, led by its truck business. Salix Pharmaceuticals, Ltd. (SLXP) and Progenics Pharmaceuticals, Inc. (PGNX) said a treatment for opioid-induced constipation met primary endpoints in a phase 3 trial. Salix Pharma's stock gained 8.7% to $47 premarket while Progenics surged 16% to $7.50. Red Hat Inc.'s (RHT) fiscal third-quarter earnings rose a stronger-than-expected 47% as the software provider's margins continued to expand. But shares dropped 7.7% to $42.50 premarket as revenue rose in line with expectations rather than topping estimates, as it had in previous quarters. Netflix Inc. (NFLX) and BBC Worldwide, the commercial arm of the BBC, unveiled a new digital licensing agreement, bringing a range of BBC shows to Netflix members in the United Kingdom and Ireland. Netflix shares traded up 1.4% to $68.08 premarket. Targacept Inc. (TRGT) and AstraZeneca PLC (AZN, AZN.LN) said their potential antidepressant TC-5214 didn't meet the primary endpoint of a Phase III study. Shares of Targacept recently dropped 26.7% premarket to $5.70, while AstraZenec was trading 1% lower at $44.99. TransCanada Corp. (TRP) is buying nine solar projects in Ontario from Canadian Solar Solutions Inc. (CSIQ) for about C$470 million (US$452.5 million) as part of its strategy of expanding its portfolio of alternative or renewable-energy assets. Shares of Canadian Solar jumped 24% to $2.75 premarket. ImmunoGen Inc. (IMGN) agreed to a collaboration with Eli Lilly & Co. (LLY) potentially valued at roughly $220 million in which the pharmaceutical giant will get exclusive licensing rights to some of the drug developer's antibody-based cancer therapies. Shares of Immunogen added 5.6% to $12 premarket. Watch List: AllianceBernstein Holding LP (AB) said the leader of its sell-side research subsidiary would assume the role of chief operating officer of the fund manager, as part of organizational changes to streamline management. Amgen Inc. (AMGN) and Watson Pharmaceuticals Inc. (WPI) agreed to work together on several cancer antibody biosimilar products, which they expect to sell under a joint label. Under the deal, Amgen will lead the development, manufacturing and initial commercialization of the oncology antibody products. Watson will initially receive royalties and sales milestones from product revenues, and it will contribute up to $400 million in codevelopment costs as well as share product development risks. Commercial Metals Co.'s (CMC) board recommended that shareholders reject Carl Icahn's unsolicited $1.73 billion tender offer as the scrap-metal processor also projected fiscal first-quarter earnings far above Wall Street estimates thanks to a tax benefit. ConAgra Foods Inc.'s (CAG) fiscal second-quarter earnings fell 14% after being hit with hedging losses. The packaged-food company also reported its consumer-foods unit was hurt by rising commodities costs. However, its smaller commercial foods segment saw better-than-expected profit growth and adjusted earnings beat analysts' expectations. Moody's Investors Service put Constellation Energy Group Inc. (CEG) on review for a possible upgrade from the brink of junk after it and proposed merger partner Exelon Corp. (EXC) reached secured support from Maryland officials. Standard & Poor's Ratings Services heightened the chance of an upgrade for Pall Corp. (PLL), citing solid credit metrics and good operating performance by the maker of filtration and purification products. Sanderson Farms Inc. (SAFM) swung to a fourth-quarter loss as the poultry producer's margins continued to sink amid high feed costs, while most selling prices also slid. Sempra Energy (SRE) said it will likely meet or exceed the high end of its previous full-year earnings guidance following broad-based improvement in operating performance. The power company is slated to report its full-year results on Feb. 28. Southwestern Energy Co. (SWN) said it plans to boost its capital investment to $2.3 billion in 2012, compared with this year's $2.1 billion outlay, as it looks to boost natural gas production in regions like Pennsylvania's Marcellus Shale region. Vulcan Materials Co. (VMC) said it will streamline its business units and could cut about 200 jobs in a bid to lower costs amid a hostile takeover bid. -Edited by Corrie Driebusch and Ian Thomson; write to corrie.driebusch@dowjones.com and ian.thomson@dowjones.com

Stock News for Immunogen (IMGN)
DateTimeHeadline
02/22/201312:20:15FDA Approves Breast-Cancer Drug
02/22/201311:40:34FDA Approves Kadcyla, Breast-Cancer Drug from Roche, ImmunoGen
11/07/201212:39:53U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
11/06/201218:06:12FDA Gives Priority Review to ImmunoGen, Roche Breast Cancer Drug
08/27/201208:28:12ImmunoGen Breast Cancer Drug Shows Positive Results; Shares Up
12/20/201112:53:08CORRECT: ImmunoGen To Collaborate With Lilly On Cancer Drugs
12/20/201109:18:02US Stock Futures: HOT STOCKS TO WATCH
12/20/201107:34:12ImmunoGen To Collaborate With Lilly On Cancer Drugs
12/10/201019:32:18Immunogen-Roche Breast-Cancer Drug Has Positive Response In Early...
10/11/201007:30:09ImmunoGen Cuts Year Forecast, Announces Positive Study Results
10/11/201004:43:44Novartis And Immunogen To Co-Produce Cancer Drugs
08/18/201013:45:05ImmunoGen Receives Orphan Drug Status For Lung Cancer Drug

Immunogen and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad